Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.1 (
ACS
)
78,556
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A novel nitrogen-phosphorus flame retardant (P-N FR) based on phosphonamidate, dimethyl
N
,
N
'-1,3-phenylenebis(P-methylphosphonamidate) (DMPMP), was successfully synthesized and its flame-retarding performances and thermal degradation were compared with those of other P-N FRs and a phosphorus-based FR such as resorcinol bis(diphenyl phosphate) (
RDP
). DMPMP was applied to acrylonitrile-butadiene-styrene (ABS) and ethylene-vinyl acetate (EVA) to investigate the factors governing the flame-retarding behaviors of P-N FRs which would make them efficient for noncharrable polymers. V-0 ratings were achieved at 20 wt % loading of DMPMP for ABS and at a much lesser amount of DMPMP loading (10 wt %) for EVA. Meanwhile, no rating and V-2 were achieved even at 20-30 wt % loading of other P-N FRs or
RDP
for ABS and EVA, respectively. The results from thermogravimetric analysis, Fourier transform infrared, and UL-94V indicated that DMPMP is a highly efficient FR and acts mainly in a gas-phase flame-retarding mode of action. The condensed phase of DMPMP also contributed to the flame retardancy property through -NH- groups which tendentiously generate a nitrogen-phosphorus-rich residue because of the intermolecular coupling transesterification reaction. These results demonstrated the assumption that DMPMP has a high P content and good hydrostability, which exhibits good flame retardancy for noncharrable polymers such as ABS and EVA.
ACS
Omega 2019 Oct 29
PMID:Novel Nitrogen-Phosphorus Flame Retardant Based on Phosphonamidate: Thermal Stability and Flame Retardancy. 3168 85